Amgen stock holds steady as earnings and guidance frame the outlook

Amgen Inc. (ISIN US0311621009) remains a closely watched large-cap health care name after fiscal 2025 revenue reached $33.5 billion and non-GAAP diluted EPS came to $20.49, two figures that set the baseline for 2026 comparisons. The stock also sits inside the S&P 500, which keeps every earnings update relevant for broad-market funds and sector investors.

Fiscal 2025 sets the base

Amgen reported fiscal 2025 total revenue of $33.5 billion, up from $28.2 billion in 2024, a year-over-year increase of about 18.8%. Non-GAAP operating income reached $13.4 billion in 2025, while non-GAAP diluted EPS rose to $20.49 from $18.58 a year earlier, giving investors a clearer view of earnings power than the top line alone.

Free cash flow was $11.9 billion in 2025, and cash and cash equivalents stood at $11.0 billion at year-end, a mix that supports the company’s capital allocation profile. Net product sales also rose to $32.4 billion in 2025 from $27.4 billion in 2024, showing that the revenue base still depends heavily on marketed medicines rather than one-off items.

Margins still matter

The margin picture improved with non-GAAP operating income at $13.4 billion on $33.5 billion of revenue in 2025, which implies a margin of roughly 40%. That level matters because Amgen is still carrying major research, manufacturing, and commercial costs while trying to convert product growth into durable earnings growth.

Research and development expense was $5.6 billion in 2025, while selling, general and administrative expense was $5.1 billion, so the company is still spending heavily to defend and expand its portfolio. Those figures matter more than narrative optimism, because they show how much of the cash engine must be reinvested before it reaches shareholders.

Portfolio drive

Amgen’s product mix remains the central operating question. Even with broad revenue growth, investors usually focus on whether legacy franchises can offset spending on newer products and whether free cash flow can remain near the $11.9 billion level seen in 2025.

The company’s 2025 report also showed that total operating expenses remained elevated, which makes the next annual comparison important for margin direction. A revenue base of $33.5 billion can absorb pressure, but only if product sales continue to rise faster than cost growth.

Repatha remains important

Repatha is one of Amgen’s better-known products and remains useful as a reference point for how the company turns clinical franchises into sales. In a portfolio of this size, investors tend to judge each large branded medicine on its ability to contribute to the $32.4 billion net product sales base without eroding margin.

The product mix matters because Amgen is not just a single-drug story. The 2025 numbers show a diversified commercial base, and that diversification is what helps stabilize earnings when one franchise slows or a launch takes longer to scale.

Stock context

Amgen stock is normally valued on earnings durability, cash generation, and product mix rather than on a single quarter. The clearest dated anchor in the current profile is fiscal 2025, where revenue of $33.5 billion, free cash flow of $11.9 billion, and non-GAAP EPS of $20.49 give the market a concrete framework for 2026 comparisons.

In the absence of a fresh quoted move, the most useful market reference is the company’s standing as a large S&P 500 health care constituent with a 2025 earnings base that implies a high cash-generating profile. For investors, the next read-through will come from whether 2026 revenue can extend beyond $33.5 billion while keeping the cost structure from overtaking growth.

Read deeper into Amgen’s latest financial profile through the company’s investor relations materials and the 2025 report, which together frame the key 2026 comparison points.

Amgen medicines

Repatha remains a practical product lens because it represents the kind of branded franchise that can move the mix in a business of Amgen’s size. When the portfolio expands, the key question is not just sales growth but whether high-value medicines can keep supporting the company’s margin profile and cash conversion.

That is why the 2025 product and profit figures matter together. Revenue of $33.5 billion, free cash flow of $11.9 billion, and non-GAAP EPS of $20.49 all point to a business with substantial operating scale.

Amgen shares

Amgen shares are best read through earnings and cash flow rather than a single headline catalyst. With fiscal 2025 already setting a higher base than 2024, the stock case now depends on whether management can keep sales, margins, and capital returns aligned in 2026.

For the latest comparable base, the key numbers are still fiscal 2025 revenue of $33.5 billion, net product sales of $32.4 billion, and free cash flow of $11.9 billion.